FTC finds Grifols' US acquisition anticompetitive

19 September 2018
mergers-acquisitions-big

Following a public comment period, the US Federal Trade Commission has approved a final order that settles charges that Catalan pharma-chemical company Grifols’ (Nasdaq: GRFS) $286 million acquisition of USA-based Biotest Pharmaceuticals is anticompetitive and violates federal antitrust law.

According to the complaint, the acquisition as originally proposed would have given Grifols a monopoly  in the markets for collection of human blood plasma in Lincoln, Nebraska, Augusta, Georgia, and Youngstown, Ohio. The settlement requires Grifols to divest its plasma collection centers in these three cities to KedPlasma, a subsidiary of Kedrion Biopharma. Kedrion Biopharma is a leading manufacturer of protein products and is the fifth-largest producer of plasma proteins worldwide.

Also HBIG competition concerns

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical